These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18680438)

  • 61. Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.
    Jiang H; Zeng J; Li W; Bifano M; Gu H; Titsch C; Easter J; Burrell R; Kandoussi H; Aubry AF; Arnold ME
    Anal Chem; 2012 Nov; 84(22):10031-7. PubMed ID: 23106420
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts.
    Garner RC; Barker J; Flavell C; Garner JV; Whattam M; Young GC; Cussans N; Jezequel S; Leong D
    J Pharm Biomed Anal; 2000 Dec; 24(2):197-209. PubMed ID: 11130199
    [TBL] [Abstract][Full Text] [Related]  

  • 63. When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies.
    Arnold ME; Lacreta F
    Bioanalysis; 2012 Aug; 4(15):1831-4. PubMed ID: 22943612
    [No Abstract]   [Full Text] [Related]  

  • 64. Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene.
    Lightfoot TJ; Coxhead JM; Cupid BC; Nicholson S; Garner RC
    Mutat Res; 2000 Dec; 472(1-2):119-27. PubMed ID: 11113704
    [TBL] [Abstract][Full Text] [Related]  

  • 65. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry.
    Higton D; Young G; Timmerman P; Abbott R; Knutsson M; Svensson LD
    Bioanalysis; 2012 Nov; 4(22):2669-79. PubMed ID: 23210650
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter.
    Minamimoto R; Hamabe Y; Cheng C; Shimoda M; Oka T; Inoue T
    Ann Nucl Med; 2010 Jan; 24(1):45-52. PubMed ID: 20013358
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Accelerator mass spectrometry for quantification of micro- and therapeutic-dose diclofenac in microdialysis samples.
    Langer O; Song J; Choi MS; Lackner E; Bergmann F; Yeo CS; Kwon M; Kwon M; Shim JH; R Dueker S; Zeitlinger M; Bauer M
    Bioanalysis; 2022 Aug; 14(16):1111-1122. PubMed ID: 36165918
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
    Young GC; Corless S; Felgate CC; Colthup PV
    Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
    Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
    Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biases affecting injected doses of an experimental drug during clinical trials.
    Perrottet N; Brunner-Ferber F; Grouzmann E; Spertini F; Biollaz J; Buclin T; Widmer N
    Trials; 2016 Jul; 17(1):321. PubMed ID: 27423899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Accelerator mass spectrometry-enabled studies: current status and future prospects.
    Arjomand A
    Bioanalysis; 2010 Mar; 2(3):519-41. PubMed ID: 20440378
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers.
    Klem B; Lappin G; Nicholson S; van de Wetering J; de Vries DE; Oosterhuis B; Garner RC
    J Clin Pharmacol; 2006 Apr; 46(4):456-60. PubMed ID: 16554454
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics in the calf of a long-acting chloramphenicol formulation administered intravenously and intramuscularly.
    Bousquet E
    Ann Rech Vet; 1990; 21 Suppl 1():47S-55S. PubMed ID: 2080847
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The application of human phase 0 microdosing trials: A systematic review and perspectives.
    Svendsen P; El-Galaly TC; Dybkær K; Bøgsted M; Laursen MB; Schmitz A; Jensen P; Johnsen HE
    Leuk Lymphoma; 2016; 57(6):1281-90. PubMed ID: 26428262
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate.
    Salehpour M; Håkansson K; Höglund U; Grahn-Westin A; Nilsson S; Márquez M; Possnert G; Holmberg AR
    Rapid Commun Mass Spectrom; 2011 Sep; 25(17):2453-8. PubMed ID: 21818805
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic development of quinolone antibiotics.
    Schaefer HG; Ahr G; Kuhlmann J
    Int J Clin Pharmacol Ther; 1995 May; 33(5):266-76. PubMed ID: 7655765
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
    DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches.
    Beaumont C; Young GC; Cavalier T; Young MA
    Br J Clin Pharmacol; 2014 Dec; 78(6):1185-200. PubMed ID: 25041729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.